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Risk of Gastrointestinal Bleeding 
Among Dabigatran Users – A Self 
Controlled Case Series Analysis
Wenze Tang1, Hsien-Yen Chang2,3, Meijia Zhou2 & Sonal Singh2,4,5
This article aims to evaluate the real world risk of gastrointestinal bleeding among users naïve to 
dabigatran. We adopted a self-controlled case series design. We sampled 1215 eligible adult participants 
who were continuous insured users between July 1, 2010 and March 31, 2012 with use of dabigatran and 
at least one gastrointestinal bleeding episode. We used a conditional Poisson regression to estimate 
incidence rate ratios. The population consisted of 64.69% of male and 60.25% patients equal to or greater 
than age 65 at start of observation. After adjustment for time-variant confounders, the incidence rate of 
gastrointestinal bleeding was similar during dabigatran risk period and non-exposed period (incidence 
rate ratio [IRR] = 1.01, 95% confidence interval [CI] 0.90, 1.15). There was no significant difference in GI 
incidence rate between periods of dabigatran and warfarin (IRR = 0.99, 95% CI 0.75–1.31). Among this 
database of young and healthy participants, dabigatran was not associated with increased incidence rate 
of GI bleeding compared with non-exposed period among naïve dabigatran users. We did not detect an 
increased risk of GI bleeding over dabigatran vs warfarin risk period. Along with other studies on safety and 
effectiveness, this study should help clinicians choose the appropriate anticoagulant for their patients.
Oral anticoagulants are effective in preventing thromboembolic events among patients with atrial fibrillation1. In 
2010, dabigatran was approved by the United States Food and Drug Administration as an alternative to warfarin, 
a widely used anticoagulant. Dabigatran etexilate, a prodrug, is converted into its active moiety, dabigatran, in 
the gastrointestinal (GI) tract, plasma and liver2. Its relative advantages include fewer medication interactions, 
no required monitoring and simple dosing. Dabigatran has transient pharmacologic effects; the half-life of dab-
igatran is 10–12 hours only3. It is excreted primarily via kidney, thus patients with impaired renal function have 
a prolonged half-life4. The relative efficacy and non-inferiority of dabigatran compared to warfarin have been 
established by clinical trials5,6. In Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial, 
dabigatran administered at a dose of 150 mg twice per day was associated with lower rates of stroke, systemic 
embolism and serious intracranial bleeding compared to warfarin; dabigatran is also associated with higher rates 
of GI bleeding (relative risk 1.50, 95% confidence interval [CI]: 1.19–1.89)7,8, especially among older patients and 
patients with obesity and impaired renal function9. However, the real world effectiveness and safety of dabigatran 
also need to be evaluated in observational studies, as clinical trials were conducted on selective patients10. Several 
observational studies have adopted a traditional cohort design to evaluate this association11–14.
Despite the various potential adverse effects of anticoagulant, GI bleeding is of particular concern due to its 
mortality and morbidity. In the United States, more than 140,000 hospital admissions involved the principal diag-
noses of GI hemorrhage not otherwise specified, causing in total 612,000 days of hospital stay and an aggregate 
cost of over 1 trillion USD in 200915; among these hospitalized, 3.5% died. In the United Kingdom (UK), 103 
out of 100,000 adults experience upper GI bleeding per year; the rate is even higher among the elderly16. Those 
hospitalized in UK for acute upper GI bleeding had a mortality rate of 10% in 200717. Among patients with atrial 
fibrillation in the UK, fatality rates of GI bleeding attributable to warfarin use is as high as 6%18.
We used a self-controlled case series design to compare the relative safety of dabigatran regarding the risk 
of GI bleeding among users naïve to dabigatran using claims data. Claims data has been used widely in health 
1Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington 
University, Washington, District of Columbia, USA. 2Center for Drug Safety and Effectiveness, Johns Hopkins 
Bloomberg School of Public Health, Baltimore, Maryland, USA. 3Department of Health Policy & Management, 
Bloomberg School of Public Health, Baltimore, USA. 4Division of General Internal Medicine, Johns Hopkins Medicine, 
Baltimore, Maryland, USA. 5Department of Family Medicine and Community Health, University of Massachusetts 
Medical School, Worcester, Massachusetts, USA. Correspondence and requests for materials should be addressed to 
H.-Y.C. (email: hchang24@jhmi.edu)
received: 17 June 2016
Accepted: 02 December 2016
Published: 20 January 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:40120 | DOI: 10.1038/srep40120
services research and pharmacoepidemiology studies to examine the real-world impact, relative to the restricted 
environment under randomized controlled studies12,15,19,20. The self-controlled case series (SCCS) design has 
been used to study association between transient exposure and acute outcome of interest21,22. SCCS examines 
how incidence rate of outcome within the same individual differs between the periods exposed to drugs under 
investigation and the non-exposed period (Fig. 1). The design has four implications: first, each subject can have 
multiple exposures and experience multiple events; second, the risk period with drug exposure can be com-
pared against another drug exposure or the non-exposed period; third, the observation period can also serve as a 
period to determine study population eligibility (e.g. the study population is restricted to individuals who experi-
enced at least one outcome event); fourth, the intra-person comparison implicitly controls for all time-invariant 
confounders23.
Methods
Data Source. We used commercial LifeLink Health Plan Claims Data compiled by IMS Health under a data 
usage agreement. Data files can be made available to academic researchers on request as long as it does not vio-
late the terms of agreement and provided that the researchers sign a confidentiality statement and receive IMS 
approval for their request. This dataset contained private health insurance plan information from managed care 
plans and other sources (such as Medicare and Medicaid) across the United States. It is considered to be repre-
sentative of the nation’s commercially insured population24. Two parts of the dataset were used; enrollment files 
contained each individual’s enrollment history (both medical and pharmacy), region, together with individual 
demographics. Claims files included all the diagnosis documented as International Classification Disease, Ninth 
Revision, Clinical Modification (ICD-9), procedures as the Current Procedural Terminology codes (CPT-4) or 
the Healthcare Procedural Coding System (HCPCS), prescription as National Drug Code (NDC), date of ser-
vices, and the number of days with drug supply. For age information, only year of birth was available. Therefore, 
the birth date of each individual was set to the middle day of the year (i.e. June 30). The data source included 
de-identified information so this project was deemed not to be human subject research by the institutional review 
board of the Johns Hopkins Bloomberg School of Public Health.
Inclusion Criteria. Our observation period spanned from July 1, 2010 to March 31, 2012 (i.e. 21 months). 
We restricted our study subjects to those (1) not having exposed to warfarin or dabigatran between July 1,2010 
and October 19, 2010, when dabigatran first obtained administrative approval (i.e. naive user design), (2) never 
having exposed to rivaroxaban throughout the observation period, (3) having continuous medical and pharmacy 
enrollment throughout the observation period, (4) at least 18 years old on July 1, 2010, (5) having at least one 
unique GI bleeding case during the observation period, and (6) having experienced dabigatran risk period and 
at least one of the two following periods: period with no exposure (i.e. non-exposed period) and warfarin risk 
period; participants with only warfarin, dabigatran or non-exposed risk period were removed as these partic-
ipants did not transition between periods of exposure/non-exposed and therefore did not contribute to SCCS 
analysis.
Outcome of Interest: GI Bleeding. We used ICD-9 and CPT codes to identify 7 types of GI bleeding cases 
(Appendix 2). This algorithm has been validated in a previous study and the positive predictive value was 83%25. 
We only counted the first GI bleeding case if two cases of the same type occurred within 7 days based on the acute 
course of most episodes of GI bleeding.
Sample Size. We assumed that the episodes of GI bleeding were independent. We estimated that 398 epi-
sodes of GI bleeding would be needed during dabigatran risk periods to detect an effect size of 1.25 comparing 
dabigatran against warfarin risk period with 80% power and 95% confidence interval26.
Figure 1. Diagram of typical risk periods in self-controlled case series design. 
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Exposure/Non-exposed Period Definition. The exposed risk period of dabigatran and warfarin were 
separately defined as the days of supply following the dispense event plus a grace period of 14 days3; the grace 
period is the washout period following the end of medication supply to account for residual effects of drug 
exposure.
Warfarin exposure was considered continuous if two warfarin risk periods overlapped. The same was applied 
to dabigatran. If the risk periods of one warfarin and another dabigatran overlapped (e.g. the patient switched 
from warfarin to dabigatran or vice versa), the start date of second drug’s risk period was considered the end date 
of the first drug’s risk period. The unassigned time period where participant took neither warfarin nor dabigatran 
was designated as the non-exposed period (Fig. 1).
Statistical Analysis. We used conditional Poisson regression model to estimate the incidence rate ratio 
(IRR). We used SAS version 9.3 for data management and analyses. SAS coding for the data management and 
analyses is readily accessible as a supplementary file.
We also adjusted for time-dependent covariates to minimize the impact of confounders26. We considered 
the following variables as potential time-dependent confounders: age groups, co-medication use [proton 
pump inhibitors (PPIs), steroids, P-glycoprotein (PGP) inhibitors and nonsteroidal anti-inflammatory drugs 
(NSAIDs)], development of specific chronic conditions (renal failure, trauma and H. pylori infection) and the 
HAS-BLED bleeding score to concomitantly account for bleeding-related risk factors including Hypertension, 
Abnormal renal/ liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, 
Elderly and Drugs/alcohol27–29. The lower the HAS-BLED bleeding score, the less bleeding-related comorbidities 
presented. All time-variant covariates were treated as categorical. However, age group, development of renal fail-
ure and H pylori infection were excluded from adjusted model because less than 5% of the subjects experienced 
status change throughout the entire observational period in the primary analyses or any of the sensitivity analy-
ses (Appendix 3). We divided the entire study period into seven 3-month segments and for each participant we 
generated a HAS-BLED score over each three-month period using ICD-9 diagnosis codes. We also designated 
an indicator of covariates for each of these periods; if a comedication was used for more than 14 days, the med-
ication was considered to have been used during that three-month period. If certain chronic condition were 
recorded within one three-month period, that three-month period was considered exposed to that condition. 
These three-month periods containing HAS-BLED score as well as covariate indicators were merged with expo-
sure risk periods. This way, all three-month periods could be further segmented by the risk periods of dabigatran, 
warfarin and non-exposure. We further categorized HAS-BLED scores into 3 levels (i.e. 0, 1, > = 2) based on its 
distribution in adjusted model.
Sensitivity Analyses. We conducted various sensitivity analyses to test the robustness of our results. 
We stratified risk periods to those with HAS-BLED bleeding score > = 1 and those with HAS-BLED bleeding 
score = 0 to test the impact of levels of bleeding risk on the outcome. We stratified risk periods into the above two 
levels to avoid a decrease in sample size. We also stratified subjects by age groups at baseline: those older than 65 
versus 65 or younger.
To test the validity of exposure grace periods, we also used 7 days of grace period for both exposures. In addi-
tion, due to the inability of prescription data on warfarin to reliably estimate the days of warfarin exposure, 30 
days of grace period at the end of warfarin prescription date were tested in the sensitivity analysis.
We also conducted an analysis using prevalent user design by allowing the inclusion of participants who had 
been using warfarin in the three months before dabigatran became available.
Results
We identified 1,215 adult continuous enrollees with at least one GI bleeding event and dabigatran use between 
July 1, 2010 and March 31, 2012. Among these dabigatran users, 24.12% (i.e. 293 patients) switched between 
dabigatran and warfarin and 64.69% were male. At the onset of the study, 60.25% were older than 65 years. Nearly 
70% of the patients were at the lowest two levels of bleeding risk score (i.e. 0 and 1) over the first 3 months of 
observation. Over the same period, 24.94%, 8.56%, 6.01% and 14.81% had used PPI, steroids, PGP inhibitors and 
NSAID respectively. Throughout the 21 months of the study, 14.24%, 40.58% and 1.81% of subjects developed 
renal failure, trauma and H. pylori infection, respectively (Table 1).
List of potential indications for dabigatran use were summarized in appendix 1 stratified by age groups, iden-
tified using ICD-9 code of atrial fibrillation and venous thromboembolism that took place during the 12 months 
prior to patient’s dabigatran initiation.
The mean exposed duration of dabigatran and warfarin use were 159 and 114 days respectively. The mean 
non-exposed duration was 448 days. Over the risk period of dabigatran, warfarin and non-exposed, there were 
470, 84 and 1,159 episodes of GI bleeding during the risk period of dabigatran, warfarin and non-exposed risk 
periods, respectively (Table 2).
Dabigatran vs Non-exposed Period. Compared with non-exposed period, the incidence rate of GI bleed-
ing was 1.23 times higher for patients during the dabigatran risk period (IRR: 1.23, 95% CI: 1.09–1.39). After 
adjusting for bleeding score, use of NSAIDs, PPIs, PGP inhibitors and steroid medications as well as development 
of trauma, dabigatran showed similar risk of GI bleeding with non-exposed period (IRR: 1.01, 95% CI: 0.90–1.15) 
(Table 3).
Dabigatran vs Warfarin Period. In both unadjusted and adjusted model, compared with warfarin risk 
period, dabigatran risk period was not associated with significant increase in the risk of GI bleeding (unadjusted 
IRR: 1.02, 95% CI: 0.77–1.34, adjusted IRR: 0.99, 95% CI: 0.75–1.31) (Table 3).
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Among all available confounders, HAS-BLED score equal to or greater than 1, and concomitant use of PPIs 
were significant risk factors with p < 0.05 (Appendix 4).
Sensitivity Analyses. In stratified analyses, IRRs comparing dabigatran risk period against non-exposed 
period were 1.05 (95% CI: 0.92–1.20) and 1.03 (95% CI: 0.71–1.51) for risk periods with HAS-BLED score > 0 
and HAS-BLED score = 0 respectively. IRRs comparing dabigatran risk period against warfarin risk period were 
1.00 (95%CI: 0.74–1.33) and 0.65 (95% CI: 0.25, 1.71), for risk periods with HAS-BLED score > 0 and HAS-BLED 
score = 0 respectively (Appendix 5 and Appendix 6).
Variables N %
Age Groupsa
 18–44 23 1.89
 45–54 103 8.48
 55–64 357 29.38
 65+ 732 60.25
Sex
 Male 786 64.69
Region
 East 110 9.05
 North West 339 27.90
 South 606 49.88
 West 160 13.17
HAS-BLED Score Level over first three monthsb
 0 308 25.35
 1 541 44.53
 > = 2 366 30.12
Co-medication over first three monthsb
 Proton pump inhibitors 303 24.94
 Steroid 104 8.56
 P-glycoprotein Inhibitor 73 6.01
 Nonsteroidal anti-inflammatory drugs 180 14.81
Ever developed listed chronic conditionsc
 renal failure 173 14.24
 trauma 493 40.58
 H. pylori infection 22 1.81
Table 1. Characteristics of dabigatran users during the study period (N = 1215). aSummarized based on the 
information on Jul 01, 2010. bSummarized over the first three months of the observation period, i.e. from Jul 01, 
2010 to Sep 30, 2010. cSummarized based on the whole observation period.
Variables No Drug Exposure Warfarin exposure Dabigatran exposure
#of patients with the specified risk period 1215 293 1215
#of GI bleeding episodes unique to each of the risk period 1159 84 470
Mean individual risk period in days (Range) 448(101–632) 114(1–431) 159 (1–503)
Median individual risk period in days (IQR) 476 (356–555) 89 (43–153) 128 (50–241)
Table 2.  Number of cases of GI bleeding within each exposure risk period (Number of gastrointestinal 
bleeding = 1,713). GI-Gastrointestinal, IQR-Interquartile range.
Drug Comparison
IRR (95% CI)
Unadjusted model Adjusted model
Dabigatran vs Non-exposed 1.23* (1.09, 1.39) 1.01 (0.90, 1.15)
Warfarin vs Non-exposed 1.21 (0.93, 1.57) 1.02 (0.78, 1.33)
Dabigatran vs Warfarin 1.02 (0.77, 1.34) 0.99 (0.75, 1.31)
Table 3.  Incidence rate ratio of gastrointestinal bleeding by different groups. IRR-Incidence rate ratio, CI-
Confidence interval. *p < 0.05.
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The cohort younger than or equal to 65 years old had a significantly increased risk during warfarin risk 
periods compared to non-exposed period (IRR = 2.73, 95%CI: 1.14–6.53) while IRR comparing dabigatran vs 
non-exposed risk periods were similar in both younger and older cohort (Age > 65: IRR = 1.02, 95CI: 0.90–1.15 
and age < = 65 years: IRR = 0.98, 95CI: 0.58–1.65). There was a 64% significant decrease in incidence rate among 
the younger cohort when they were on dabigatran compared to when they were on warfarin (IRR = 0.36, 95% CI: 
0.14–0.93, Appendix 7).
Sensitivity analyses with various grace period assumptions produced similar results to the primary analyses 
(Appendix 4).
By including prevalent warfarin users into our study population (who switched to dabigatran after dabigatran 
became available), we found that after adjusting for time-dependent covariates, dabigatran risk period was asso-
ciated with 12% significantly higher risk of GI bleeding compared with the non-exposed period (95% CI: 1.02–
1.23). IRR comparing dabigatran risk period against warfarin risk period also indicated significantly increased 
risk of GI bleeding (IRR = 1.13, 95CI: 1.00–1.27) (Appendix 8).
Discussion
In this group of the commercially insured enrollees with no prior use of warfarin, periods of dabigatran use was 
not associated with increased risk of GI bleeding, compared to periods of non-exposure. Dabigatran and warfarin 
use seem to be associated with similar risk of GI bleeding.
Our findings of similar risk of GI bleeding associated with dabigatran and warfarin bears similarities and 
differences with results of recent randomized controlled trials and some observational studies. One previous 
meta-analyses of clinical trials reported an significantly increased risk for GI bleeding associated with dabigatran 
compared to warfarin (OR = 1.58, 95% CI: 1.29–1.93)9. An FDA study focusing on the elderly Medicare patients 
with non-valvular atrial fibrillation also found a similarly increased risk with dabigatran relative to warfarin 
(OR = 1.28, 95% CI: 1.14–1.44)13. However, our result is in line with most recent retrospective cohort studies 
from Denmark and US both of which reported no significant increase in GI bleeding with dabigatran relative to 
warfarin11,12,14. The Danish study found that naïve dabigatran users on a 110 mg regimen had 47% significantly 
lower risk of GI bleeding compared with warfarin users(IRR = 0.53, 95%CI: 0.28–0.98)) while dabigatran users 
who switched from warfarin had insignificant higher risk of GI bleeding compared with persistent warfarin 
users(IRR = 1.22, 95% CI: 0.73–2.03)14. Our analysis of prevalent warfarin users suggests that switchers from 
warfarin to dabigatran are at significantly higher risk of developing GI bleeding, relative to warfarin exposure or 
non-exposed.
Our statistically insignificant results when comparing new dabigatran use to warfarin could be explained by 
the younger cohort and its associated lower comorbidity level, as indicated by our stratified analyses. The rela-
tively short average duration of dabigatran and warfarin might limit the accumulation of bleeding risk. In contrast 
to our study, dabigatran was found to significantly increase the risk of GI bleeding in the Medicare cohort com-
pared to warfarin, as it involved older participants with comorbidities30.
Our study provides several novel findings on the gastrointestinal safety of dabigatran topic. First, we were 
able to assess the relative risk of GI bleeding comparing dabigatran use against no anticoagulant use whereas 
previous studies have only been able to provide estimates comparing dabigatran use against warfarin. Second, 
unlike a case-control study with a binary outcome or cohort study with a time-to-event/censoring, the SCCS 
design allows for recurrent episodes of GI bleeding and estimates the average risk over a duration of person-time 
(incidence rate)31. In addition, unlike other studies where confounders may only be treated as baseline constant, 
we controlled for important confounders including overall bleeding-related risk factors that are time-variant. This 
allowed for within-person change of risk level along time. Our study showed that higher bleeding-related risk 
level of the patients and PPI use as co-medication were both strong and consistent confounders for the association 
between dabigatran and GI bleeding. We used a validated algorithm to identify GI bleeding cases and performed 
several sensitivity analyses to evaluate the robustness of our results.
Our study has some limitations. First, the assumption that previous GI bleeding would not alter the proba-
bility of being exposed to the drugs following that event could be violated and introduce reverse causality bias; 
in clinical practice, patient are usually asked to temporarily suspend novel anticoagulant for 2–3 weeks after a GI 
bleeding event occurs. In order to adjust for the reverse causality bias, we used the standard bidirectional design 
setting, where risk periods before(i.e. pre-exposure risk periods) and after the first exposure event were both 
included for analysis21,32. Although the exact timing of drug discontinuation is unknown and will depend on 
clinical context, it is less likely that the anticoagulant disruption after a GI bleeding event would either last longer 
than 3 months or lead to more immediate re-exposure to anticoagulant as the clinical conditions which mandated 
anticoagulation (e.g. atrial fibrillation and venous thromboembolism) pose a continuing risk for patients. As a 
result, our estimate could be biased towards either direction but is more likely to be biased away from the null 
if reverse causality persists. Readers should interpret our results with such acknowledgment. Second, the drug 
dispensing and supply information in data may not necessarily represent real world adherence. Although we used 
7, 14 and 30 days of grace period for warfarin, risk window definition of warfarin was still somewhat uncertain 
given the inability of prescription data on warfarin to accurately estimate its duration. PPI and NSAID use might 
also be underestimated as both are available over the counter and we did not have information on aspirin use. 
Third, even though we used a validated algorithm to identify GI bleeding, potential misclassification of outcome 
is possible since we did not validate the claims in this database. This would bias our results to the null. Fourth, 
our findings may be subject to unmeasured time-variant confounding, such as laboratory testing of prothrombin 
times, and other time-variant residual confounding. Fifth, we did not assess long-term outcomes such as stroke 
due to the fact that a much longer follow-up time is necessary for this study. Sixth, the administrative claims we 
used did not have sufficient information on mortality, therefore we did not exclude participants who died imme-
diately after the last outcome event but before the end of observation period. This could bias the estimate towards 
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either direction. Seventh, HAS-BLED score has only been validated for warfarin’s GI bleeding risk among atrial 
fibrillation patients, therefore, it may not be generalizable to other populations. Finally, our non-significant esti-
mates of GI bleeding associated with warfarin exposed period vs non-exposed risk periods should be interpreted 
with caution because of insufficient sample size.
Conclusion
In this database of relatively young and healthy commercially insured participants, dabigatran was not associated 
with increased incidence rate of GI bleeding compared with non-exposed period among new dabigatran users. 
We did not detect an increased risk of GI bleeding over dabigatran risk period vs warfarin risk period. Our study 
suggested age cohort, time-variant bleeding-related comorbidities and whether a subject is naïve dabigatran user 
could significantly modify their risk of GI bleeding associated with dabigatran and warfarin. Our study should 
provide additional information on the relative safety of dabigatran. Along with other studies on the efficacy, effec-
tiveness and safety of anticoagulants, this study would help clinicians prescribe the appropriate anticoagulant for 
their patients.
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